NTLA-2002 in Adults With Hereditary Angioedema (HAE)
This research study is looking into a new treatment called NTLA-2002 for adults who have Hereditary Angioedema (HAE) Type 1 or Type 2. HAE is a condition that causes sudden swelling attacks. The main goals of this study are to check if NTLA-2002 is safe, how well your body tolerates it, and if it helps reduce or prevent HAE attacks. Researchers will also be looking at how the medicine works in your body over time. This is an early stage of testing for NTLA-2002, meaning it's one of the first times it's being given to people. If you're an adult with HAE and are interested in new treatment options, this study might be for you.
De un vistazo
¿De qué trata este estudio?
Hereditary Angioedema (HAE) is a rare genetic condition that causes unpredictable and often severe swelling attacks. These attacks can affect various parts of the body, including the skin, gut, and airways, and can be very painful and even life-threatening if they affect the throat. Current treatments help manage these attacks, but researchers are always looking for new and more effective ways to prevent them.
This study is investigating a new potential medicine called NTLA-2002. It's an early-stage clinical trial, which means it’s one of the first times this medicine is being tested in people. The main purpose is to carefully check if NTLA-2002 is safe for people with HAE. We also want to understand if it’s well-tolerated, meaning if people can take it without too many unwanted side effects. Beyond safety, the study aims to see if NTLA-2002 has a positive effect on HAE, helping to control or prevent new swelling attacks.
Researchers will also be monitoring how the medicine moves through your body and how your body reacts to it over time. This information is crucial for understanding how NTLA-2002 works and for deciding if it's a promising treatment that should be studied further in larger groups of people. Your participation would provide valuable information to help advance knowledge and potential treatments for HAE.
Puntos clave
- Este estudio está probando un nuevo medicamento (NTLA-2002) para el Angioedema Hereditario (HAE).
- It's an early-stage study, focused on safety and how well the medicine is tolerated.
- Adults with HAE Type 1 or Type 2 can be considered for participation.
- You might receive the new medicine or a 'dummy' treatment.
- Participation involves regular clinic visits and health checks.
- You can stop taking part at any time without affecting your care.
¿Quién puede ser elegible?
To be able to take part in this study, you must be an adult aged 18 or over and have been diagnosed with Hereditary Angioedema (HAE) Type 1 or Type 2. You’ll also need to be able to show that you've had HAE attacks and have access to and know how to use at least one medicine to treat your sudden swelling attacks.
There are also some reasons why you might not be able to join. For example, if you have another type of regular swelling condition that isn't HAE, or if you know you've had a bad reaction to similar types of medicines in the past. If the study doctor thinks that taking part in the study could put your safety at risk, or if you're not able to follow the study's instructions, then you wouldn't be able to participate. You also can't be taking part in another medical study at the same time.
¿Podría este estudio ser adecuado para ti?
Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.
- ¿Tienes 18 años o más?
- Have you been diagnosed with Hereditary Angioedema (HAE) Type 1 or Type 2?
- Do you currently have a way to treat your HAE attacks (e.g., medication)?
- Are you able to regularly attend study visits?
- Are you willing to not participate in other medical studies during this one?
- Do you have good overall health, according to your study doctor?
¿En qué consiste la participación?
If you decide to take part, you'll receive doses of either NTLA-2002 or a 'dummy' treatment (normal saline, which is just saltwater). Both are given directly into your vein. The study team will regularly check your health to see how you're doing, gather blood and urine samples, and record any side effects you might experience. This helps them understand the safety and effects of the treatment.
You'll have regular hospital visits for assessments and to receive the treatment. The total length of your participation is not specified but will involve several visits over a period of time. You'll also need to be willing to follow all the study procedures carefully and avoid joining any other medical studies while this one is ongoing.
Riesgos y beneficios potenciales
Locations (9)
- Clinical Trial SiteCódigo postal verificadoCampbelltown, Australia
- Clinical Trial SiteCódigo postal verificadoGrenoble, Francia
- Clinical Trial SiteCódigo postal verificadoLille, Francia
- Clinical Trial SiteCódigo postal verificadoParís, Francia
- Clinical Trial SiteCódigo postal verificadoBerlín, Alemania
- Clinical Trial SiteCódigo postal verificadoFráncfort, Alemania
- Clinical Trial SiteCódigo postal verificadoÁmsterdam, Países Bajos
- Clinical Trial SiteCódigo postal verificadoAuckland, Nueva Zelanda
- Clinical Trial SiteCódigo postal verificadoCambridge, Reino Unido
Preguntas comunes
¿Qué es el Angioedema Hereditario (HAE)?
HAE is a rare inherited condition that causes sudden and painful swelling attacks in various parts of the body, such as the skin, throat, or gut.
¿Qué es NTLA-2002?
NTLA-2002 is an experimental medicine being tested in this study to see if it can help adults with Hereditary Angioedema.
Will I definitely receive the new medicine?
In this study, you might receive NTLA-2002 or a 'dummy' treatment called normal saline, which is a saltwater solution. This is common in studies to help researchers compare the effects.
¿Cómo se administrará el medicamento?
Both NTLA-2002 and the 'dummy' treatment will be given to you directly into a vein (intravenously).
Can I stop participating if I want to?
Yes, you are free to leave the study at any time, for any reason, without it affecting your usual medical care.
Cómo obtener más información
Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.
Discusión
Discusión comunitaria
Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.